How do antidepressants work? New perspectives for refining future treatment approaches

The Lancet Psychiatry

Volumn 4, Issue 5, 2017, Pages 409-418

  Harmer, Catherine J ^a   Duman, Ronald S ^b   Cowen, Philip J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DULOXETINE; MIRTAZAPINE; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VILAZODONE;

ANTIDEPRESSANT ACTIVITY; CHRONIC STRESS; COGNITION; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; LONG TERM CARE; NERVE CELL PLASTICITY; NEUROPSYCHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; EMOTION; SOCIAL BEHAVIOR;

ANTIDEPRESSIVE AGENTS; DEPRESSION; EMOTIONS; HUMANS; NEURONAL PLASTICITY; SOCIAL BEHAVIOR;

EID: 85011034365     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30015-9     Document Type: Review

References (83)

1. 1 Cahn, C, Roland Kuhn, 1912–2005. Neuropsychopharmacology, 31, 2006, 1096.
2. 2 Ross, SB, Renyi, AL, Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue. Eur J Pharmacol 7 (1969), 270–277.
3. 3 Vetulani, J, Sulser, F, Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257 (1975), 495–496.
4. 4 Cleare, A, Pariante, CM, Young, AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29 (2015), 459–525.
5. 5 Bauer, M, Bschor, T, Pfennig, A, et al., for the WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8 (2007), 67–104.
6. 6 Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373 (2009), 746–758.
7. 7 Wiles, NJ, Fischer, K, Cowen, P, et al. Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. Psychol Med 44 (2014), 2855–2866.
8. 8 Turcotte, JE, Debonnel, G, de Montigny, C, Hébert, C, Blier, P, Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 24 (2001), 511–521.
9. 9 Deardorff, WJ, Grossberg, GT, A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 15 (2014), 2525–2542.
10. 10 Whiting, D, Cowen, PJ, Drug information update: agomelatine. The Psychiatrist 37 (2013), 356–358.
11. 11 Sugrue, MF, Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 21 (1983), 31–33.
12. 12 Cowen, PJ, Green, AR, Grahame-Smith, DG, Braddock, LE, Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission. Br J Clin Pharmacol 19 (1985), 799–805.
13. 13 Artigas, F, Romero, L, de Montigny, C, Blier, P, Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT 1A antagonists. Trends Neuroscie 19 (1996), 378–383.
14. 14 Scorza, MC, Lladó-Pelfort, L, Oller, S, et al. Preclinical and clinical characterization of the selective 5–HT1A receptor antagonist DU–125530 for antidepressant treatment. Br J Pharmacol 167 (2012), 1021–1034.
15. 15 Citri, A, Malenka, R, Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33 (2008), 18–41.
16. 16 McEwen, BS, Bowles, N, Gray, J, et al. Mechanisms of stress in the brain. Nat Neurosci 18 (2015), 1353–1363.
17. 17 McEwen, BS, Morrison, JH, The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. Neuron 79 (2013), 16–29.
18. 18 Miller, BR, Hen, R, The current state of the neurogenic theory of depression and anxiety. Curr Opin Neurobiol 30 (2015), 51–58.
19. 19 Price, JL, Drevets, WC, Neurocircuitry of mood disorders. Neuropsychopharmacology 35 (2010), 192–216.
20. 20 MacQueen, G, Frodl, T, The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?. Mol Psychiatry 16 (2011), 252–264.
21. 21 Roozendaal, B, McEwen, BS, Chattarji, S, Stress, memory and the amygdala. Nat Rev Neurosci 10 (2009), 423–433.
22. 22 Russo, SJ, Nestler, EJ, The brain reward circuitry in mood disorders. Nat Rev Neurosci 14 (2013), 609–625.
23. 23 Popoli, M, Yan, Z, McEwen, BS, Sanacora, G, The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13 (2012), 22–37.
24. 24 Duman, RS, Monteggia, LM, A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59 (2006), 1116–1127.
25. 25 Castren, E, Neurotrophins and psychiatric disorders. Handb Exp Pharmacol 220 (2014), 461–479.
26. 26 Chen, Z-Y, Jing, D, Bath, KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314 (2006), 140–143.
27. 27 Liu, RJ, Lee, FS, Li, XY, Bambico, F, Duman, RS, Aghajanian, GK, Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 71 (2012), 996–1005.
28. 28 Duman, R, Aghajanian, G, Synaptic dysfunction in depression: novel therapeutic targets. Science 338 (2012), 68–72.
29. 29 Duman, R, Aghajanian, A, Sanacora, G, Krystal, J, A synaptic hypothesis of depression: new insights from studies of stress systems and rapid-acting antidepressant. Nat Med 22 (2016), 238–249.
30. 30 Björkholm, C, Monteggia, LM, BDNF—a key transducer of antidepressant effects. Neuropharmacology 102 (2016), 72–79.
31. 31 Ota, K, Liu, RJ, Voleti, B, et al. REDD1 is essential for stress-induced synaptic loss and depressive behaviour. Nat Med 20 (2014), 531–535.
32. 32 Jernigan, CS, Goswami, DB, Austin, MC, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 35 (2011), 1774–1779.
33. 33 Krishnan, V, Nestler, EJ, Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167 (2010), 1305–1320.
34. 34 Magarinos, AM, McEwen, BS, Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 69 (1995), 89–98.
35. 35 Bessa, J, Ferreira, D, Melo, I, et al. Hippocampal neurogenesis induced by antidepressant drugs: an epiphenomenon in their mood-improving actions. Mol Psych, 14, 2009, 739.
36. 36 Maya Vetencourt, JF, Sale, A, Viegi, A, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 320 (2008), 385–388.
37. 37 Karpova, NN, Pickenhagen, A, Lindholm, J, et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 334 (2011), 1731–1734.
38. 38 Carlezon, WA Jr, Duman, RS, Nestler, EJ, The many faces of CREB. Trends Neurosci 28 (2005), 436–445.
39. 39 Krishnan, V, Nestler, EJ, The molecular neurobiology of depression. Nature 455 (2008), 894–902.
40. 40 Taliaz, D, Stall, N, Dar, DE, Zangen, A, Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry 15 (2010), 80–92.
41. 41 Nestler, E, ΔFosB: a transcriptional regulator of stress and antidepressant responses. Eur J Pharmacol 753 (2015), 66–72.
42. 42 Kendler, KS, Kuhn, J, Prescott, CA, The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am J Psychiatry 161 (2004), 631–636.
43. 43 Disner, SG, Beevers, CG, Haigh, EA, Beck, AT, Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 12 (2011), 467–477.
44. 44 Roiser, JP, Sahakian, BJ, Hot and cold cognition in depression. CNS Spectr 18 (2013), 139–149.
45. 45 Lewis, G, Kounali, D, Button, KS, et al. Reduced bias for the processing of socially rewarding information in people with depressive symptoms: evidence for depressive realism in a prospective longitudinal cohort. Acta Psychiatrica Scandinavica, 2017 (in press).
46. 46 Harmer, CJ, Goodwin, GM, Cowen, PJ, Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195 (2009), 102–108.
47. 47 Phillips, ML, Drevets, WC, Rauch, SL, Lane, R, Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 54 (2003), 515–528.
48. 48 Harmer, CJ, O'Sullivan, U, Favaron, E, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 166 (2009), 1178–1184.
49. 49 Harmer, CJ, Cowen, PJ, Goodwin, GM, Efficacy markers in depression. J Psychopharmacol 25 (2011), 1148–1158.
50. 50 Tranter, R, Bell, D, Gutting, P, Harmer, CJ, Healy, D, Anderson, IM, The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord 118 (2009), 87–93.
51. 51 Shiroma, PR, Thuras, P, Johns, B, Lim, KO, Emotion recognition processing as early predictor of response to 8-week citalopram treatment in late-life depression. Int J Geriatr Psychiatry 29 (2014), 1132–1139.
52. 52 Ironside, M, O'Shea, J, Cowen, PJ, Harmer, CJ, Frontal cortex stimulation reduces vigilance to threat: implications for the treatment of depression and anxiety. Biol Psychiatry 79 (2016), 823–830.
53. 53 Harmer, CJ, Charles, M, McTavish, S, Favaron, E, Cowen, PJ, Negative ion treatment increases positive emotional processing in seasonal affective disorder. Psychol Med 42 (2012), 1605–1612.
54. 54 Reinecke, A, Waldenmaier, L, Cooper, MJ, Harmer, CJ, Changes in automatic threat processing precede and predict clinical changes with exposure-based cognitive-behavior therapy for panic disorder. Biol Psychiatry 73 (2013), 1064–1070.
55. 55 Ma, Y, Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis. Mol Psychiatry 20 (2015), 311–319.
56. 56 Del-Ben, CM, Deakin, JF, McKie, S, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 30 (2005), 1724–1734.
57. 57 Murphy, SE, Norbury, R, O'Sullivan, U, Cowen, PJ, Harmer, CJ, Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 194 (2009), 535–540.
58. 58 Harmer, CJ, Mackay, CE, Reid, CB, Cowen, PJ, Goodwin, GM, Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59 (2006), 816–820.
59. 59 Godlewska, BR, Norbury, R, Selvaraj, S, Cowen, PJ, Harmer, CJ, Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med 42 (2012), 2609–2617.
60. 60 Fu, CH, Williams, SC, Cleare, AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 61 (2004), 877–889.
61. 61 Fu, CH, Williams, SC, Brammer, MJ, et al. Neural responses to happy facial expressions in major depression following antidepressant treatment. Am J Psychiatry 164 (2007), 599–607.
62. 62 Godlewska, G, Browning, M, Norbury, R, Cowen, PJ, Harmer, CJ, Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Transl Psychiatry, 6, 2016, e957.
63. 63 Harmer, CJ, Emotional processing as an early biomarker for the treatment response to antidepressant drugs. Neuropsychopharmacology, 26(suppl 2), 2016, 133.
64. 64 MacLeod, C, Rutherford, E, Campbell, L, Ebsworthy, G, Holker, L, Selective attention and emotional vulnerability: assessing the causal basis of their association through the experimental manipulation of attentional bias. J Abnorm Psychol 111 (2002), 107–123.
65. 65 Browning, M, Grol, M, Ly, V, Goodwin, GM, Holmes, EA, Harmer, CJ, Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety. Neuropsychopharmacology 36 (2011), 2689–2697.
66. 66 Rose, N, Neuroscience and the future for mental health?. Epidemiol Psychiatr Sci 25 (2016), 95–100.
67. 67 Berman, RM, Cappiello, A, Anand, A, et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47 (2000), 351–354.
68. 68 Maeng, S, Zarate, CA Jr, Du, J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63 (2008), 349–352.
69. 69 Li, N, Lee, B, Liu, RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
70. 70 Li, N, Liu, RJ, Dwyer, JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69 (2011), 754–761.
71. 71 Autry, AE, Adachi, M, Nosyreva, E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
72. 72 Laje, G, Lally, N, Mathews, D, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72 (2012), 17–28.
73. 73 Miller, OH, Moran, JT, Hall, BJ, Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: direct inhibition and disinhibition. Neuropharmacology 100 (2016), 17–26.
74. 74 Drevets, WC, Zarate, CA Jr, Furey, ML, Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 73 (2013), 1156–1163.
75. 75 Voleti, B, Navarria, A, Liu, R, et al. Scopolamine rapidly increases mTORC1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 74 (2013), 742–749.
76. 76 Scheidegger, M, Henning, A, Walter, M, et al. Effects of ketamine on cognition-emotion interaction in the brain. Neuroimage 124 (2016), 8–15.
77. 77 Stuart, SA, Butler, P, Munafò, MR, Nutt, DJ, Robinson, ES, Distinct neuropsychological mechanisms may explain delayed-versus rapid-onset antidepressant efficacy. Neuropsychopharmacology 40 (2015), 2165–2174.
78. 78 Zarate, CA, Niciu, MJ, Ketamine for depression: evidence, promises and challenges. World Psychiatry 14 (2015), 348–435.
79. 79 Zanos, P, Moaddel, R, Morris, PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.
80. 80 Newport, DJ, Carpenter, LL, McDonald, WM, Potash, JB, Tohen, M, Nemeroff, CB, Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172 (2015), 950–966.
81. 81 Chaki, S, Fukumoto, K, Potential of glutamate-based drug discovery for next generation antidepressants. Pharmaceuticals 8 (2015), 590–606.
82. 82 Nicoletti, F, Bruno, V, Ngomba, RT, Gradini, R, Battaglia, G, Metabotropic glutamate receptors as drug targets: what's new?. Curr Opin Pharmacol 20 (2015), 89–94.
83. 83 Stuart, SA, Butler, P, Munafò, MR, Nutt, DJ, Robinson, ES, A translational rodentassay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology 38 (2013), 1625–1635.